B4GALT2 Blocking Peptide
- Known as:
- B4GALT2 Blocking Peptide
- Catalog number:
- abx161292
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- B4GALT2 Blocking Peptide
Related genes to: B4GALT2 Blocking Peptide
- Gene:
- B4GALT2 NIH gene
- Name:
- beta-1,4-galactosyltransferase 2
- Previous symbol:
- -
- Synonyms:
- beta4Gal-T2
- Chromosome:
- 1p34.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-02
- Date modifiied:
- 2016-10-05
Related products to: B4GALT2 Blocking Peptide
Related articles to: B4GALT2 Blocking Peptide
- Immune evasion is one of the critical factors contributing to the advanced progression of colorectal cancer (CRC). Our research identified that CRC cells exhibit high expression of the zinc finger protein ZNF30, which transcriptionally activates the expression of the glycosyltransferase B4GALT2. B4GALT2 mediates the N-glycosylation of MUC20, which subsequently interacts with sialic acid-binding immunoglobulin-like lectin 7 (Siglec-7) on the surface of macrophages. This interaction induces M2 polarization of the macrophages, thereby promoting immune evasion in CRC and ultimately accelerating malignant progression. In vivo experiments also verified that the ZNF30/B4GALT2/MUC20 axis promotes the growth and metastasis of CRC. The discovery of this regulatory mechanism highlights the critical role of aberrant glycosylation of MUC20 in CRC immune evasion and offers new predictive markers and therapeutic targets for patients with advanced CRC. - Source: PubMed
Publication date: 2026/04/11
Zhi YingruZhang YifengFei HuanhuanYuan JieLiu XiaobeiLiu Wanli - Lethal prostate cancer is marked by tumor heterogeneity and resistance to androgen receptor signaling inhibitors (ARSIs). In this study we identify glycolysis as a driver of disease progression and therapy resistance. Using single-sample gene set enrichment analysis (ssGSEA) on the SU2C cohort, we demonstrate that elevated glycolysis activity is associated with poor progression-free and overall survival. The glycolysis-based prognostic score (GLY score) is derived from the HALLMARK_GLYCOLYSIS gene set which includes , , , , , and , via LASSO-Cox regression. The GLY score effectively stratifies risk in the SU2C and WDCT cohorts, with higher scores predicting worse outcomes and increased SYNE1 mutation frequency. Pan-cancer analysis across TCGA datasets confirm its prognostic value. , enzalutamide-resistant prostate cancer cell lines exhibit heightened glycolysis, and 2-DG inhibition reverses this effect, restoring drug sensitivity. knockdown reduces glycolytic activity and cell proliferation. The GLY score offers robust prognostic value, and CLN6 represents a promising therapeutic target for precision medicine in lethal prostate cancer. - Source: PubMed
Cai ZhoudaLu JianmingMo ShanshanLiu JipuZhong ChuanfanWu YongdingZou FenYe JianhengHan ZhaodongLiang YuxiangZhang LeLiu FengpingZhong Weide - Chronic pain affects one-fifth of American adults, contributing significant public health burden. Chronic pain can be further understood through investigating brain gene expression, potentially informing on brain regions, cell types, and gene pathways. We tested for differentially expressed genes (DEGs) in chronic pain, migraine, lifetime fentanyl and oxymorphone use, and with chronic pain genetic risk in 4 brain regions (dorsal anterior cingulate cortex [dACC], dorsolateral prefrontal cortex [DLPFC], medial amygdala [MeA], and basolateral amygdala [BLA]) and imputed cell type expression data from 304 deeply phenotyped postmortem donors, potentially highlighting variation relevant to factors such as predisposition to chronic pain development, mechanisms of chronic pain development and persistence, and indirect effects of chronic pain and associated treatment or medication, and substance use. We also investigated sex differences in chronic pain differential gene expression. At the brain region level, we identified 2 chronic pain DEGs: B4GALT2 and VEGFB in dACC. At the cell level, we found more than 2000 chronic pain cell-type DEGs, significantly enriched in microglia of the basolateral amygdala. The findings were enriched for mouse microglia pain genes, and for hypoxia and immune response pathways. Small amounts of cross-trait DEG overlap in migraine and chronic pain highlighted medial amygdala cells, and in chronic pain and oxymorphone use suggested the amygdala as a key region. Chronic pain differential gene expression was not significantly different between men and women. Overall, chronic pain-associated gene expression is heterogeneous across region and cell type, is largely distinct from that in pain-related factors and migraine, and our results highlight BLA microglia as a key brain cell type in chronic pain. - Source: PubMed
Publication date: 2025/07/07
Collier LilySeah CarinaHicks Emily MHoltzheimer Paul EKrystal John HGirgenti Matthew JHuckins Laura MJohnston Keira J A - - Source: PubMed
Publication date: 2025/06/12
- Lung adenocarcinoma (LUAD) presents significant challenges in prognosis and treatment efficacy evaluation. While post-translational modifications are known to influence tumor progression, their prognostic value in LUAD remains largely unexplored. - Source: PubMed
Publication date: 2025/02/25
Zhang PengpengWang DingliZhou GuangyaoJiang ShuaiZhang GeZhang LianminZhang Zhenfa